InvestorsHub Logo
Followers 105
Posts 4897
Boards Moderated 0
Alias Born 10/06/2011

Re: DR Ryan post# 363094

Thursday, 12/09/2021 11:02:45 PM

Thursday, December 09, 2021 11:02:45 PM

Post# of 404047
As noted, this is a 53 year old firm with a good brand reputation and extensive commercial reach. The reach into new ex-US markets matters because...

The US ADHD (Attention-Deficit Hyperactivity Disorder) market size stood at $4.61 billion USD in 2019 and is projected to reach $7.15 billion USD by 2025. While the global ADHD market is expected to move from $29.56 billion USD in 2021 to reach $45.68 billion USD by 2025.



It is a BFD for Elite, as revenues will be a multiple of what they are today. Then there are the new ANDAs...one of which should be a generic Vyvance that comes off patent protection in 2023...dang, there it is again...the year 2023. Vyvance has global sales that are more than twice the combined sales of Concerta and Adderall XR.




Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News